Richard Henry Jones

Title: Richard Henry Jones: Innovator in Hepatoselective Pharmaceutical Actives

Introduction

Richard Henry Jones is a notable inventor based in London, GB. He has made significant contributions to the field of pharmaceuticals, particularly in the development of hepatoselective pharmaceutical actives. With a total of 3 patents to his name, his work has the potential to impact insulin replacement therapy and other medical applications.

Latest Patents

One of Richard's latest patents focuses on hepatoselective pharmaceutical actives. This invention provides an analogue of a pharmaceutical active with a molecular weight of less than 25,000 Daltons. The analogue is covalently linked to a pendant molecular group, resulting in an active complex with a molecular weight of 25,000 Daltons or greater in the human or animal circulatory system. The analogue is particularly significant as it is hepatoselective when administered, making it a promising candidate for insulin analogues used in insulin replacement therapy.

Career Highlights

Throughout his career, Richard has worked with reputable institutions such as the Deutsches Wollforschungsinstitut and King's College. His experience in these organizations has contributed to his expertise in pharmaceutical innovations and research.

Collaborations

Richard has collaborated with notable colleagues, including Fariba Shojaee-Moradi and Peter Henri Sonksen. These partnerships have likely enriched his research and development efforts in the pharmaceutical field.

Conclusion

Richard Henry Jones is a distinguished inventor whose work in hepatoselective pharmaceutical actives showcases his innovative spirit and dedication to advancing medical science. His contributions are poised to make a significant impact in the field of pharmaceuticals.